Peptide LibraryWolverine Stack
Also known as: BPC-157 + TB-500, Wolverine blend
Wolverine Stack (also called BPC-157 + TB-500 or Wolverine blend) is a regenerative blend in the Wound Healing / Cytoprotective class. The Wolverine stack is a compounded combination of BPC-157 and TB-500 rather than a single compound, so it has no mechanism of its own beyond those of its parts.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Angiogenic / actin pathways (component-dependent)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 33
- Listed offers
- 78
- Median price per mg (peptide vials)
- $5.12/mg
- Typical $4.37–$7.75/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Peptide vials27 vendors · median $5.12/mg
- Sprays, route not stated6 vendors · $3.33–$9.70/mg
- Capsules8 vendors · $2.00–$2.08/mg
- Topicals1 vendor
Research summary
Common shop blend of BPC-157 plus TB-500. Not a single API. Both components are unapproved and WADA-relevant (BPC-157 is S0; TB-500/Tβ4 is prohibited-class).
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies1 reviewed source
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Wolverine Stack profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Wolverine Stack dosage: no established human dose
The Wolverine stack, BPC-157 and TB-500 in one vial, has no established human dosage. No human study has tested this blend, and neither component has an established human dose of its own. The closest human data is a small uncontrolled knee-pain chart review in which 4 patients received BPC-157 together with thymosin beta-4, the full-length protein rather than the TB-500 fragment.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Wolverine is a vendor blend of BPC-157 and TB-500 in one vial. Each component's evidence is mostly animal work, and a 2026 rat study that gave the two together after Achilles tendon repair found no added benefit over either peptide alone. Neither component has an established human dose, and animal doses are not converted into a human dose here.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Component (analog evidence) — BPC-157 with thymosin beta-4 (full-length protein, not TB-500): knee-pain chart review (Lee and Padgett, 2021)Clinical trial · Retrospective single-clinic chart review; uncontrolled; uses full-length thymosin beta-4, an analog of TB-500Studied an analog, not Wolverine Stack itself | Patients with knee pain of mixed causes at one clinic (16 reached by phone; 12 received BPC-157 alone and 4 BPC-157 with thymosin beta-4) | Not stated in the indexed abstract | Intra-articular | — | — | By phone survey, 3 of the 4 patients given both peptides reported significant improvement in knee pain and 1 had no relief; 11 of 12 given BPC-157 alone reported improvement. No validated outcome tools and no control group | Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. |
| Component (analog evidence) — BPC-157: NCT07437547, phase 2, recruiting, no resultsClinical trial · Registered phase 2 placebo-controlled trial of one component aloneStudied an analog, not Wolverine Stack itself | Adults with acute hamstring muscle strain (planned n=120) | Not disclosed in the registry record (BPC-157 alone, not a blend) | Subcutaneous | Once daily | 14 days | Hamstring muscle strain repair; no results posted | NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair |
| Component (analog evidence) — TB-500: NCT07487363, phase 1/2, recruiting, no resultsClinical trial · Registered phase 1/2 placebo-controlled trial of one component aloneStudied an analog, not Wolverine Stack itself | Adults with stable atherosclerotic cardiovascular disease (planned n=80) | Not disclosed in the registry record (TB-500 alone, not a blend) | Not disclosed | — | — | Cardiovascular biomarkers; no results posted | NCT07487363 — TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD |
| BPC-157 and TB-500 together — rat Achilles tendon repair (Biçer et al., 2026)Preclinical · Randomised preclinical study comparing each peptide alone and the two combined | Male Sprague-Dawley rats after Achilles tendon transection and repair (n=32, 8 per group) | BPC-157 10 µg/kg/day, TB-500 60 µg/kg/day, or both; model-specific and not convertible to a human dose | Intraperitoneal | Daily | 4 weeks | Both peptides alone improved tendon histology, and TB-500 alone improved load to failure; the combination gave no added benefit over either alone | Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026. |
Where sources disagree
- A blend's amount of BPC-157 or TB-500 is not a dose that was studied for that compound: no human study has given either peptide at a known dose by injection under the skin. See the BPC-157 and TB-500 profiles for what each component's evidence shows.
- Shop listings sell the blend as one total amount, most often 10 mg or 20 mg, and the split between BPC-157 and TB-500 (usually equal) is set by the seller. Some sellers also use the Wolverine name for other blends.
- TB-500 is a short fragment of thymosin beta-4, not the full 43-amino-acid protein. The knee-pain review used thymosin beta-4, so it is not evidence for TB-500, and the abstract does not give the doses used.
Reconstitution
Common research vial sizes: 10 mg, 20 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL of total blend | 50 mcg of total blend per 0.01 mL |
| 20 mg | 2 mL | 10 mg/mL of total blend | 100 mcg of total blend per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Appearance | White lyophilized powder |
|---|---|
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
The Wolverine stack is a compounded combination of BPC-157 and TB-500 rather than a single compound, so it has no mechanism of its own beyond those of its parts. BPC-157 is a synthetic pentadecapeptide derived from a gastric protein, reported in animal models to promote angiogenesis through VEGFR2 and focal adhesion kinase signalling and to modulate the nitric oxide system. TB-500 supplies the actin-binding motif of thymosin beta-4, associated with cell migration and angiogenesis in preclinical work. The two are combined on the rationale that they act on complementary aspects of tissue repair, but no controlled trial has evaluated the combination, and the pharmacokinetics of co-administration are uncharacterised.
Origin
Commercial two-peptide blend.
Targets
Studies
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review (component evidence (bpc-157))
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (component evidence (bpc-157))
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (component evidence (tb-500 (thymosin beta-4 fragment)))
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine (component evidence (tb-500 (thymosin beta-4 fragment)))
Regulatory & research status
Wolverine Stack is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Wolverine Stack side effects
Wolverine Stack has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Injection reactions
- Component-specific unknowns
Stacking
Common stacking partners
Combinations that include Wolverine Stack, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Wolverine Stack: frequently asked questions
What is Wolverine Stack?
Common shop blend of BPC-157 plus TB-500. Not a single API. Both components are unapproved and WADA-relevant (BPC-157 is S0; TB-500/Tβ4 is prohibited-class).
How does Wolverine Stack work?
The Wolverine stack is a compounded combination of BPC-157 and TB-500 rather than a single compound, so it has no mechanism of its own beyond those of its parts. BPC-157 is a synthetic pentadecapeptide derived from a gastric protein, reported in animal models to promote angiogenesis through VEGFR2 and focal adhesion kinase signalling and to modulate the nitric oxide system.
Is Wolverine Stack FDA approved?
No. Wolverine Stack is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
Is Wolverine Stack banned in sport?
Wolverine Stack is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Wolverine Stack?
Compounds most often compared with Wolverine Stack include BPC-157, TB-500 (Thymosin Beta-4 fragment), KPV and Pentadeca Arginate. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- WADA Prohibited List 2026External reference
- Component evidence (BPC-157) — Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent ReviewExternal reference
- Component evidence (BPC-157) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewExternal reference
- Component evidence (TB-500 (Thymosin Beta-4 fragment)) — Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic PerformanceExternal reference
- Component evidence (TB-500 (Thymosin Beta-4 fragment)) — Peptide Supplements and Their Therapeutic Applications in Sports MedicineExternal reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Wolverine Stack profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Wolverine Stack research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →